



EXPRESS MAIL NO.: EV 654 849 595 US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of:	Stavenhagen et al.	Confirmation No.:	8663
Application No.:	10/754,922	Art Unit:	1643
Filed:	January 9, 2004	Examiner:	Tungaturthi, Parithosh K.
For:	Identification and Engineering of Antibodies with Variant Fc Regions and Methods of Using Same	Attorney Docket No.:	11183-004-999

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. § 1.56 AND § 1.97

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 and § 1.97 to inform the Patent and Trademark Office of all references coming to the attention of each individual associated with the filing or prosecution of the subject application, which are or may be material to the patentability of any claim of the application, Attorneys for Applicants hereby direct the Examiner's attention to references **A01-A33**, **B01-B27**, and **C01-C144**, which are listed on the attached List of References Cited by Applicant. Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. patents and published U.S. applications (*i.e.*, references A01-A33) are not submitted herewith. Copies of references **B01-B27** and **C01-C144** are submitted herewith.


Identification of the listed references is not to be construed an admission of Applicants or Attorneys for Applicants that such references are available as "prior art" against the subject application.

Applicants respectfully request that the Examiner review the foregoing references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b)(3), since this Information Disclosure Statement is being filed before the mailing of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: April 19, 2006



Margaret B. Brivanlou

JONES DAY

222 E. 41st Street

New York, New York 10017

(212) 326-3939

40,922

(Reg. No.)



Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR
	A01	2003/0158389	08/21/03	Idusogie et al.	
	A02	2004/0002587	1/1/04	Watkins et al.	
	A03	2004/0110226	6/10/04	Lazar et al.	
	A04	2004/0132101	7/8/04	Lazar et al.	
	A05	2004/0185045	9/23/04	Koenig et al.	
	A06	2005/0054832	3/10/05	Lazar et al.	
	A07	4,752,601	06/21/88	Hahn	
	A08	5,348,876	09/20/94	Michaelson et al.	
	A09	5,576,184	11/19/96	Better et al.	
	A10	5,585,089	12/17/96	Queen et al.	
	A11	5,624,821	4/29/97	Winter et al.	
	A12	5,648,260	07/15/97	Winter et al.	
	A13	5,698,449	12/16/97	Baumann et al.	
	A14	5,723,584	3/3/98	Schatz	
	A15	5,736,135	4/7/98	Goeddel et al.	
	A16	5,736,137	04/07/98	Anderson et al.	
	A17	5,874,239	2/23/99	Schatz	
	A18	5,932,433	8/3/99	Schatz	
	A19	5,985,599	11/16/99	Mckenzie et al.	
	A20	6,025,485	2/15/00	Kamb et al.	
	A21	6,114,147	9/5/00	Frenken et al.	
	A22	6,165,745	12/26/00	Ward et al.	
	A23	6,194,551	2/27/01	Idusogie et al.	
	A24	6,242,195	06/05/01	Idusogie et al.	
	A25	6,277,375	08/21/01	Ward	
	A26	6,300,065	10/9/01	Kieke et al.	
	A27	6,331,391	12/18/01	Wittrup et al.	
	A28	6,423,538	7/23/02	Wittrup et al.	
	A29	6,455,263	9/24/02	Payan	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY. DOCKET NO. 11183-004-999	APPLICATION NO. 10/754,922
APPLICANT Stavenhagen et al.	
FILING DATE January 9, 2004	ART UNIT 1643

U.S. PATENT DOCUMENTS

	A30	6,528,624	03/04/03	Idusogie et al.	
	A31	6,538,124	03/25/03	Idusogie et al.	
	A32	6,737,056	5/18/04	Presta	
	A33	6,821,505	11/23/04	Ward	

FOREIGN PATENT DOCUMENTS

		FOREIGN PATENT DOCUMENT COUNTRY CODE, NUMBER, KIND CODE (IF KNOWN)	DATE	NAME	PAGES, COLUMNS, LINES, WHERE RELEVANT PASSAGES OR RELEVANT FIGURES APPEAR	T
	B01	EP 0 327 378	0809/89	The Trustees of Columbia University		
	B02	WO 88/07089	09/22/88	Medical Research Council		
	B03	WO 89/07142	08/10/89	Morrison, S.		
	B04	WO 92/16562	10/01/92	Lynxvale Limited		
	B05	WO 93/22332	11/11/93	Board of Regents, University of Texas System		
	B06	WO 94/18330	8/18/94	Unilever PLC		
	B07	WO 94/29351	12/22/94	Morgan, S. et al.		
	B08	WO 95/05468	02/23/95	Lynxvale Limited		
	B09	WO 97/28267	08/07/97	Repligen Corporation		
	B10	WO 97/34631	09/25/97	Board of Regents, The University of Texas System		
	B11	WO 97/44362	11/27/97	Protein Design Labs, Inc.		
	B12	WO 98/05787	02/12/98	Bristol-Myers Squibb Company		
	B13	WO 98/23289	06/04/98	The General Hospital Corporation		
	B14	WO 98/52975	11/26/98	Duetsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts		
	B15	WO 99/43713	09/02/99	Lexigen Pharmaceuticals Corporation		
	B16	WO 99/51642	10/14/99	Genentech, Inc		
	B17	WO 99/58572	11/18/99	Cambridge University Technical Services Limited		
	B18	WO 00/09560	02/24/00	Abgenix, Inc.		
	B19	WO 00/42072	7/20/00	Genenech, Inc.		

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

FOREIGN PATENT DOCUMENTS

	B20	WO 02/060919	08/0802	Medimmune, Inc.		
	B21	WO 02/086070	10/31/02	Dyax Corporation, Inc.		
	B22	WO 03/074679	09/12/03	Xencor		
	B23	WO 04/029207	04/08/04	Xencor		
	B24	WO 04/074455	09/02/04	Applied Molecular Evolution, Inc.		
	B25	WO 04/099249	11/18/04	Xencor		
	B26	WO 05/070963	08/04/05	Applied Molecular Evolution, Inc.		
	B27	WO 06/020114	02/23/06	Applied Molecular Evolution, Inc.		

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Altman et al., Phenotypic Analysis of Antigen-Specific T Lymphocytes", Science 274:94-96, 1996
	C02	Angal et al., Mol Immunol 30 :105-108, 1993
	C03	Armour et al., Biochemical Society Transactions 30 :495-500, 2002
	C04	Armour et al., Eur J Immunol 29 :2613-2624, 1999
	C05	Armour et al., Mol Immunol 40 :585-593, 2003
	C06	Baggiolini M, Dewald B. Experientia. Oct 15;44(10):841-848, 1988
	C07	Boder and Wittrup, 1997, "Yeast surface display for screening combinatorial polypeptide libraries", Nature Biotechnology 15:553-557
	C08	Boder and Wittrup, Biotechnol Prog 14:55-62, 1998
	C09	Boder and Wittrup, Methods in Enzymology 328:430-444, 2000
	C10	Boder et al., Proc. Natl. Acad. Sci. USA 97:10701-10705, 2000
	C11	Bredius et al., Immunology 83:624-630, 1994
	C12	Brekke et al., Eur J Immunol 24:2542-2547, 1994
	C13	Brown EJ., Vol. 45 (Microbes as Tools for Cell Biology) in <i>Methods In Cell Biololgy</i> , Russell ed. Academic Press Inc. pp.147-64, 1994
	C14	Burlmeister et al., Nature 372:379-383, 1994
	C15	Burton and Woof, Advances in Immunology 51:1-84, 1992
	C16	Burton et al., Mol Immunol 25:1175-1181, 1988
	C17	Burton, Mol Immunol 22:161-206, 1985
	C18	Canfield and Morrison, J Exp Med 173:1483-1491, 1991
	C19	Caron et al., J Exp Med 176 :1191-5, 1992
	C20	Carter et al., Proc. Natl. Acad. Sci. USA 89:4285-4289, 1992

EXAMINER**DATE CONSIDERED**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11183-004-999	10/754,922
	APPLICANT Stavenhagen et al.	
	FILING DATE	ART UNIT
	January 9, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C21	Catron et al., Blood 99 :754-758, 2002
C22	Chappel et al., Proc. Natl. Acad. Sci USA 88:9036-9040, 1991
C23	Chappel et al., J Biol. Chem 268:25124-25131, 1993
C24	Ciccimarra et al., PNAS 72 :2081-2083, 1975
C25	Clynes and Ravetch, Immunity 3:21-26, 1995
C26	Clynes et al., J Exp Med 189:179-185
C27	Clynes et al., Nature Medicine 6 :443-446, 2000
C28	Clynes et al., PNAS 95:652-656, 1998
C29	Clynes et al., Science 279:1052-1054, 1998
C30	de Haas, Wien Kin Wochenscha 113:825-831, 2001
C31	Deisenhofer, Biochem. 20:2361-2370, 1981
C32	Deo et al., Immunology Today 18:127-135, 1997
C33	Duncan and Winter, Nature 332 :738-740, 1988
C34	Duncan and Winter, Nature 332:563-564, 1988
C35	Flesch and Neppert, J Clin Lab Anal 14:141-156, 2000
C36	Gergeley et al., Biochemical Society Transactions 12:739-743, 1984
C37	Gergely and Sarmay, FASEB J 4:3275-3283, 1990
C38	Greenwood and Clark, Effector functions of matched sets of recombinant human IgG subclass antibodies. (final version edited Feb. 11, 1993)
C39	Greenwood et al., Eur J Immunol 23:1098-1104, 1993
C40	Greenwood et al., Therapeutic Immunology 1:247-255, 1994
C41	Hadley et al., Immunology 76:446-451, 1992
C42	Hatta et al., Genes and Immunity 1:53-60, 1999
C43	Hayes, Fc Engineering to Enhance Monoclonal Antibody Effector Functions. (Presentation) Xecor, CA, 2003
C44	Herzenberg et al., Clinical Chem. 2002:48:1819-1827, 2002
C45	Heyman, Annu Rev Immunol 18:709-737, 2000
C46	Hogarth et al., Immunomethods 4 :17-24, 1994
C47	Holler et al., PNAS 97 :5387-92, 2000
C48	Hulett et al., J. Biol. Chem. 269:15287-15293, 1994
C49	Hulett et al., J. Biol. Chem. 270:21188-21194, 1995
C50	Hulett et al., J Immunol 147 :1863-1868, 1991

EXAMINER	DATE CONSIDERED
-----------------	------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C51	Idusogie et al., J Immunol 164: 4178-4184, 2000
C52	Idusogie et al., J Immunol 166 :2571-2575, 2001
C53	Isaacs et al., Clin Exp Immunol 106 :427-433, 1996
C54	Isaacs et al., J Immunol 148 :3062-3071, 1992
C55	Isaacs et al., J Immunol 161 :3862-3869, 1998
C56	Jassal et al., Biochem Soc Trans 26 :S113, 1998
C57	Jefferis and Lund, Immunology Letters 82 :57-65, 2002
C58	Jefferis et al., Immunol Lett 44 :111-7, 1995
C59	Jefferis et al., Immunol Rev 163:59-76, 1998
C60	Jefferis et al., Mol Immunol 27 :1237-1240, 1990
C61	Jendeberg et al., J Immunological Methods 201 :25-34, 1997
C62	Kadar et al., Immunol Lett 32:59-63, 1992
C63	Kadar et al., Int J Immunopharmacol 13 :1147-55, 1991
C64	Kato et al., J Mol Biol 295:213-224, 2000
C65	Keler et al., J. of Immunol. 164:5746-52, 2000
C66	Kieke et al., PNAS 96 :5651-56, 1999
C67	Kim et al., J Mol Evol 53:1-9, 2001
C68	Klein et al., PNAS 78 :524-528, 1981
C69	Koene et al., Blood 90 :1109-1114, 1997
C70	Kranz et al., J. Biol. Chem. 257:6987-6995, 1982
C71	Lehmann et al., J Immunol Methods. 243(1-2):229-42, 2000
C72	Lehrnbecher et al., Blood 94:4220-4232, 1999
C73	Li et al., J Exp Med 183 :1259-1263, 1996
C74	Liu et al., J. Immunol. 139:3521-3526, 1987
C75	Lund et al., Eur J Biochem 267 :7246-57, 2000
C76	Lund et al., FASEB J 9 :115-119, 1995
C77	Lund et al., J Immunol 147 :2657-62, 1991
C78	Lund et al., J Immunol 157 :4963-4969, 1996
C79	Lund et al., Molecular Immunology 29:53-59, 1992
C80	Maenaka et al., J Biol Chem 48 :44898-904, 2001
C81	Michaelsen et al., Immunolgy 91 :9243-9247, 1994

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
 (Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C82	Morgan et al., Immunology 86 :319-324, 1995
C83	Morrison et al., Immunologist 2 :119-124, 1994
C84	Munn et al., J Exp Med. 172(1):231-7, 1990
C85	Nagarajan et al., J Biol Chem 270 :25762-25770, 1995
C86	Neuberger et al., Nature 312 :604-608, 1984
C87	Norderhaug et al., Eur J Immunol 21:2379-84, 1991
C88	Nose and Leanderson, Eur J Immunol 19 :2179-81, 1989
C89	Okazaki et al., J Mol Biol 336 :1239-1249, 2004
C90	Orfao and Ruiz-Arguelles, Clinical Biochem. 29:5-9, 1996
C91	Partridge et al., Mol Immunol. 23(12):1365-72, 1986
C92	Perussia "Human Natural Killer Cell Protocols" in <i>Methods Molecular Biology</i> . vol. 121 (Campbell et al. eds.) Humana Press Inc., Totowa, NJ. 179-92, 2000
C93	Radaev and Sun, Molecular Immunology 38 :1073-1083, 2001
C94	Ravetch and Bolland, Annu Rev Immunol 19:275-90, 2001
C95	Ravetch and Clynes, Annu Rev Immunol 16:421-432, 1998
C96	Ravetch and Kinet, Annu Rev Immunol 9:457-492, 1991
C97	Ravetch and Lanier, Science 290:84-89, 2000
C98	Redpath et al., Hum Immunol 59 :720-727, 1998
C99	Reff et al., Blood 83:435-445, 1994
C100	Riechmann et al., Nature. 332(6162):323-7, 1988
C101	Sarmay et al., Eur J Immunol 18 :289-294, 1988
C102	Sarmay et al., Mol Immunol 21 :43-51, 1984
C103	Sarmay et al., Mol Immunol 29 :633-639, 1992
C104	Sautes-Fridman et al., ASHI Quarterley, 4 th Quarter:148-151, 2003
C105	Schaffner et al., Mol Immunol 32 :9-20, 1995 (Erratum in 32 :1299, 1995)
C106	Schatz et al., Bio/Technology 11:1138-1143, 2000
C107	Sensel et al., Molecular Immunology 34:1019-1029, 1997
C108	Shields et al., J Biol Chem 276 :6591-6604, 2001
C109	Shopes et al., J Immunol 145 :3842-3848, 1990
C110	Shopes, J Immunol 148 :2918-2922, 1992
C111	Shopes, Molecular Immunology 30 :603-609, 1993

EXAMINER


DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for Form 1449A LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	APPLICATION NO.
	11183-004-999	10/754,922
	APPLICANT Stavenvhagen et al.	
	FILING DATE	ART UNIT
	January 9, 2004	1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)		
	C112	Shusta et al., J Mol Biol 292:949-956, 1999
	C113	Shusta et al., Nature Biotechnology 16:773-777, 1998
	C114	Shusta et al., Nature Biotechnology 18:754-759, 2000
	C115	Smith and Morrison, Bio/Technology 12:683-688, 1994
	C116	Sondermann and Oosthuizen, Immunology Letters, 82:51-56, 2002
	C117	Sondermann et al., J. Mol. Biol. 309:737-749, 2001
	C118	Sondermann et al., EMBO J 18:1095-1103, 1999
	C119	Sondermann et al., Nature 406:267-273, 2000
	C120	Steplewski et al., PNAS 85:4852-4856, 1988
	C121	Strohmeier et al., J Leukocyte Biol 58:415-422, 1995
	C122	Sylvestre and Ravetch, Immunity 5:387-390, 1996
	C123	Sylvestre and Ravetch, Science 265:1095-1098, 1994
	C124	Takai et al., Cell 76 :519-529, 1994
	C125	Takai et al., Nature 379:346-349, 1996
	C126	Takai, Nature Reviews 2:580-592, 2002
	C127	Tamm et al., J Biol Chem 271:3659-3666, 1996
	C128	Tao et al., J Exp Med 173:1025-1028, 1991
	C129	Tao et al., J Exp Med 178:661-667, 1993
	C130	Van Sorge et al., Tissue Antigens 61:189-202, 2003
	C131	VanAntwerp and Wittrup, Biotechnol Prog 16:31-37, 2000
	C132	Vidarte, J Biol Chem 276:38217-38233, 2001
	C133	Ward and Ghetie, Therapeutic Immunology 2:77-94, 1995
	C134	Weng and Levy J Clin Oncol 21:3940-3947, 2003
	C135	Wing et al., J Clin Invest 98 :2819-2826, 1996
	C136	Wingren et al., Scand J Immunol 44:430-436, 1996
	C137	Wittrup, Nat Biotechnol 18:1039-1040, 2000
	C138	Witttrup, Curr. Opin. Biotechnol. 12:395-399, 2001
	C139	Woof et al., Mol Immunol 23 :319-330, 1986
	C140	Wu et al., J Clin Invest 100 :1059-1070, 1997
	C141	Xu et al., J Biol Chem 269 :3469-3474, 1994
	C142	Yeung and Wittrup, Biotechnol Prog 18:212-220, 2002

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	



Substitute for Form 1449A

LIST OF REFERENCES CITED BY APPLICANT
(Use several sheets if necessary)

ATTY. DOCKET NO.

11183-004-999

APPLICATION NO.

10/754,922

APPLICANT

Stavenhagen et al.

FILING DATE

January 9, 2004

ART UNIT

1643

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

C143 Zeidler et al., British J Cancer 83:261-266, 2000

C144 Zuckier et al., Cancer Res 58 :3905-3908, 1998

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.